Managing menopause symptoms after breast cancer: non-hormonal options

After breast cancer, hot flashes and vaginal dryness are common, often intensified by tamoxifen, aromatase inhibitors, or treatment-induced menopause, and estrogen is usually not an option. The good news is that most of the non-hormonal treatments on the menu have been tested in breast cancer survivors specifically, and one new drug, elinzanetant, was approved in 2025 with a trial dedicated to women on endocrine therapy. The key constraint is the tamoxifen interaction with certain antidepressants.

Why this group is different

Hot flashes and night sweats affect 65% to 85% of women after breast cancer treatment. The Menopause Society notes that tamoxifen and aromatase inhibitors lower estrogen or block its effects, which can intensify both hot flashes and vaginal symptoms. If symptoms are making it hard to stay on endocrine therapy, say so; treating them is part of cancer care.

Systemic hormone therapy is generally avoided after hormone-receptor-positive breast cancer. That leaves the non-hormonal options reviewed in The Menopause Society’s 2023 position statement, several of which were studied first in cancer survivors.

Hot flashes: what the trials in survivors show

Venlafaxine. The landmark trial randomized 191 evaluable women with a history of breast cancer (or fear of it) to placebo or venlafaxine 37.5, 75, or 150 mg daily for 4 weeks. Median hot flash scores fell 27% with placebo, 37% at 37.5 mg, and 61% at both 75 and 150 mg. Dry mouth, reduced appetite, nausea, and constipation were more common at 75 and 150 mg. Venlafaxine does not meaningfully inhibit CYP2D6, making it the usual antidepressant choice with tamoxifen.

Oxybutynin. In a 150-woman trial where 65% were taking tamoxifen or an aromatase inhibitor, oxybutynin 5 mg twice daily reduced weekly hot flash frequency by 7.5 episodes versus 2.6 for placebo over 6 weeks, and the lower 2.5 mg dose by 4.8. Hot flash scores and quality of life also improved. Dry mouth, difficulty urinating, and abdominal pain were more common, mostly mild. The position statement rates oxybutynin Level I-II and notes that long-term anticholinergic use may be associated with cognitive decline in older adults.

Gabapentin. A pooled analysis of three gabapentin trials found it reduced hot flashes 35% to 38% more than placebo at 4 weeks. The tamoxifen concern raised for some antidepressants does not apply to it, and its sedation can help night sweats.

Elinzanetant. OASIS-4 randomized 474 women aged 18 to 70 with moderate to severe hot flashes from endocrine therapy for hormone-receptor-positive breast cancer or its prevention, 2:1 to elinzanetant 120 mg daily or placebo. From a baseline of about 11.5 flashes a day, elinzanetant reduced daily frequency by 7.8 at week 12 versus 4.2 for placebo, a difference of 3.4 episodes (95% CI 2.5 to 4.2). The most common side effects were headache, fatigue, and somnolence; serious adverse events occurred in 2.5% versus 0.6% during the first 12 weeks. The FDA approved elinzanetant (Lynkuet) on October 24, 2025, for moderate to severe vasomotor symptoms due to menopause.

Fezolinetant. Its SKYLIGHT trials enrolled general postmenopausal populations, not women on endocrine therapy, so evidence in this group is limited. Its label states it does not inhibit CYP2D6, but it requires liver monitoring and is contraindicated with CYP1A2 inhibitors.

CBT. MENOS 1 randomized 96 breast cancer survivors with at least 10 problematic flashes a week to six weekly group CBT sessions or usual care. The hot flash problem rating fell 1.67 points (on a 10-point scale) more than usual care at 9 weeks and 1.76 at 26 weeks, with benefits to mood, sleep, and quality of life. MENOS 4 showed breast care nurses could deliver it, with a 46% reduction in problem rating versus 15% for usual care.

Clinical hypnosis. In 60 breast cancer survivors with at least 14 flashes a week, five weekly hypnosis sessions reduced hot flash scores 68% from baseline and improved anxiety, depression, and sleep versus no treatment.

Stellate ganglion block. The position statement describes a 40-patient breast cancer study comparing this nerve-block injection with paroxetine 7.5 mg over 6 weeks, in which both helped, and rates the procedure Level II-III with a caution about procedural risks.

The tamoxifen interaction

Tamoxifen is a prodrug converted by the CYP2D6 enzyme into endoxifen, its most active form. Paroxetine and fluoxetine are strong CYP2D6 inhibitors. The Brisdelle label says it is uncertain whether the combination significantly reduces tamoxifen’s efficacy, that some studies showed a higher risk of recurrence and others did not, and that clinicians should weigh the benefit against possible reduced tamoxifen effectiveness. The Menopause Society’s advice is simpler: choose venlafaxine, desvenlafaxine, escitalopram, or citalopram instead. The CYP2D6 concern is specific to tamoxifen and these antidepressants; it is not raised for gabapentin, oxybutynin, CBT, or hypnosis. Ask your oncologist about any new drug you add.

Vaginal and sexual symptoms

Aromatase inhibitors in particular cause severe vaginal dryness and pain with sex. The 2020 Menopause Society statement on genitourinary syndrome of menopause recommends starting with regular vaginal moisturizers (two to three times a week), lubricants for sex, and pelvic floor physical therapy. One small crossover study in breast cancer survivors found silicone-based lubricant more helpful than water-based.

If those fail, the statement lists topical lidocaine, low-dose vaginal estrogen, vaginal DHEA, and ospemifene as options to discuss with oncology. Low-dose vaginal estrogen is contraindicated by FDA class labeling after breast cancer, but the statement notes serum estradiol stays in the postmenopausal range with the tablet, insert, and ring, that ACOG has endorsed its use including in ER-positive disease, and that many oncologists allow it when non-hormonal measures fail. Vaginal DHEA is not contraindicated but labeling advises caution. Ospemifene is not recommended after breast cancer because it has not been adequately studied in this group.

How the options compare

Option	Trial in breast cancer survivors	Effect	Avoid with tamoxifen?	Main drawbacks
Venlafaxine 75 mg	Yes (n=191)	61% vs 27% placebo in score at 4 weeks	No (listed as a safer choice)	Dry mouth, nausea, constipation
Oxybutynin 5 mg twice daily	Yes (n=150, 65% on endocrine therapy)	7.5 vs 2.6 fewer flashes/week	Not flagged	Dry mouth, urinary difficulty, cognitive concern long term
Gabapentin 900 to 2,400 mg	General trials; no dedicated trial reviewed here	35 to 38% more than placebo	Not flagged	Drowsiness
Elinzanetant 120 mg	Yes (OASIS-4, n=474)	3.4 fewer flashes/day at week 12	Tested in women on endocrine therapy	Headache, fatigue, somnolence; newest drug
Fezolinetant 45 mg	No dedicated trial	About 2.5 fewer/day in general population	Not a CYP2D6 inhibitor	Liver tests; limited data in this group
Paroxetine, fluoxetine	Not reviewed here	Paroxetine effective; fluoxetine not recommended	Yes	CYP2D6 inhibition
Group CBT	Yes (MENOS 1, MENOS 4)	Less bother, better sleep and mood	No	Access
Clinical hypnosis	Yes (n=60)	68% reduction in score	No	Few providers

Working with your team

Your oncologist should be part of this decision, but a menopause-trained clinician often knows the non-hormonal options in more depth. How to find a menopause specialist explains what to look for, and our OB-GYN directory can help.

Questions for your clinician

• Am I on tamoxifen or an aromatase inhibitor, and does that change which antidepressant is safe?
• Would elinzanetant be appropriate given my endocrine therapy, and does my plan cover it?
• Is gabapentin at bedtime a good fit for my night sweats?
• Can I be referred to a CBT or hypnosis program with experience in cancer survivors?
• For vaginal symptoms, what is my oncologist’s position on low-dose vaginal estrogen if moisturizers are not enough?
• If symptoms are making me want to stop endocrine therapy, what can we change first?